Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta 


Charles River no tagline

 

Cofactor Genonics
 

Elsevier

 

Menarini Silicon Biosystems

 NanoString     

 SeraCare 

 Streck 

 TriMetis


XIFIN

  View All Sponsors 

Speaker Information

   

2013 Molecular Medicine Tri-Conference Speaker & Panelists* 

  • Adam Kraut, Scientific Consultant, BioTeam, Inc. 
  • Adam Margolin, Ph.D., Computational Biology, Sage Bionetworks  
  • Alan F. Feeney, Esq., Owner, Feeney Law Group 
  • Alex Cho, M.D., MBA, Assistant Professor, Department of Medicine, General Internal Medicine, DUHS Center for Personalized Medicine, Duke University  
  • Alexander Dobrovic, M.D., Head, Molecular Pathology R&D, Pathology, Peter MacCallum Cancer Centre 
  • Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope 
  • Akash Kumar, B.Chem.E, M.S., M.D./Ph.D. Candidate, Genome Sciences, University of Washington 
  • Alan Carter, Chief Business Officer, PanGenX 
  • Alex Cho, M.D., MBA, Assistant Professor, Department of Medicine, General Internal Medicine, DUHS Center for Personalized Medicine, Duke University  
  • Alexander Morley, M.D., Professor, Head, Minimal Residual Disease Group, Haematology & Genetic Pathology, Flinders University 
  • Alexandra S. Whale, Ph.D., Researcher, LCG Ltd. 
  • Ali Tinazli, Ph.D., Director, Business Development & Sales, Sony DADC  
  • Alice Jacobs, Ph.D., Chairman & CEO, IntelligentMDx 
  • Alison Betts, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism (PDM), Pfizer Worldwide Research & Development 
  • Allan T. Bombard, M.D., CMO, Sequenom 
  • Andrea L. Richardson, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Department of Cancer Biology, Dana-Farber Cancer Institute; Senior Staff Pathologist, Brigham and Women’s Hospital, Department of Pathology  
  • Andreas M. Kogelnik, M.D., Ph.D., Director, Open Medicine Institute 
  • Andreas Matern, Vice President, Disruptive Innovation, Thomson Reuters 
  • Andrew Dallas, President & CTO, Full Spectrum Software, Inc. 
  • Andrew Poklepovic, Ph.D., Assistant Professor, Internal Medicine, Virginia Commonwealth University  
  • Andro Hsu, Ph.D., Vice President, Products, GigaGen, Inc. 
  • Anil Sethi, CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur 
  • Anil V. Parwani, M.D., Ph.D., Director, Division of Pathology Informatics, University of Pittsburgh  
  • Apostolia-Maria Tsimberidou, M.D., Ph.D., Associate Professor, Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center 
  • Arnon Chait, Ph.D., President, AnalizaDx, LLC 
  • Arthur L. Beaudet, M.D., Henry and Emma Meyer Professor and Chair, Department of Molecular and Human Genetics, Baylor College of Medicine 
  • Arturo Morales, Ph.D., Global Leader Data Federation Initiative, Informatics Systems Lead, Novartis   
  • Arun Nayar, Global Head, External Collaborations, R&D, Information, AstraZeneca Pharmaceuticals 
  • Asuncion Mejias, M.D., Principal Investigator, Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital 
  • Athena Cherry, Ph.D., Director, Cytogenetics Laboratory; Professor, Pathology and Pediatrics, Stanford Comprehensive Cancer Center 
  • Austin Tanney, Ph.D., Scientific Liaison Manager, Almac Group 
  • Ayub Khattak, CEO, Ruubix, Inc. 
  • Balaji Panchapakesan (Baloo), Ph.D., Associate Professor of Mechanical Engineering, University of Louisville  
  • Barry Bunin, Ph.D. CEO, Collaborative Drug Discovery 
  • Barry Hart, Ph.D., VP, Project Mgmt. & Business Development, Allostem Therapeutics 
  • Birgit H. Funke, Ph.D., FACMG, Assistant Professor of Pathology, MGH/Harvard Medical School; Director of Clinical Research and Development, Laboratory for Molecular Medicine, PCPGM  
  • BJ Kerns, SVP, Translational Medicine, HTG Molecular Diagnostics, Inc. 
  • Bob S. Carter M.D., Ph.D., Professor and Division Chief, UCSD Neurosurgery  
  • Borna Safabakhsh, Co-Founder and CEO, Agile Diagnosis  
  • Branimir I. Sikic, M.D., Professor of Medicine, Division of Oncology, Stanford University School of Medicine 
  • Brian K. Albrecht, Ph.D., Sr. Dir., Medicinal Chemistry, Constellation Pharmaceuticals  
  • Brian T. Edmonds, Ph.D., Research Advisor, Global External Research & Development, Lilly Corporate Center 
  • Bruce K. Gale, Ph.D., Associate Professor and Director, State of Utah Center of Excellence for Biomedical Microfluidics, Department of Mechanical Engineering, University of Utah 
  • Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist. Life Science & Government Strategy & Medical Coverage & Reimbursement, Foley Hoag 
  • Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham 
  • BS Manjunath, Director, Center for Bio-image Informatics; Vice Chair and Undergraduate Program Director, Department of Electrical and Computer Engineering, University of California Santa Barbara  
  • Byron C. Hann, M.D., Ph.D., Associate Researcher, Manager of Pre-Clinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center 
  • C. Glenn Begley, Ph.D., Senior Vice President, TetraLogic 
  • Calvin B. Harley, Ph.D., CSO, Telome Health, Inc. 
  • Carlos Cordon-Cardo, M.D., Ph.D., Professor and Chairman, Department of Pathology; Professor, Department of Genetics and Genomic Sciences, The Mount Sinai School of Medicine 
  • Carol Bova Hill, Ph.D., Informatics Project Leader II, Clinical Research Informatics, Duke Clinical Research Institute  
  • Casey Eitner, Senior Vice President, Business Development, Vitatex, Inc. 
  • Cedo Bagi, M.D., Ph.D., Senior Research Fellow, Worldwide Comparative Medicine, Global Science & Technology, Pfizer Global R&D 
  • Cecilia Schott, Pharm.D., M.B.A., Executive Business Development Director, Personalized Healthcare, AstraZeneca 
  • Cha-Mei Tang, Sc.D., President and CEO, Creatv MicroTech, Inc. 
  • Chaminda Selgado, Ph.D., Head of Department, CMC Bioassay & Genomics, NDA-Analytics 
  • Charles Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen 
  • Chiang J. Li, M.D., FACP, President, CEO & CMO, Boston Biomedical, Inc; Head, Global Oncology, Dainippon Sumitomo Pharma Group 
  • Chris Higgs, Senior Applications Scientist, Schrodinger 
  • Chris L. Waller, Ph.D., Director, Cheminformatics, Discovery Merck Research Labs  
  • Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group 
  • Christina Lu, Manager, IT, Novartis Pharmaceuticals Corp.  
  • Christine M. Eng, M.D., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine 
  • Christopher A. Moskaluk, M.D., Ph.D., David Harrison Distinguished Teaching Professor of Pathology, University of Virginia Health System 
  • Christopher J. O’Donnell, Ph.D., Sr. Director, Oncology Medicinal Chemistry, Pfizer 
  • Claude Dufresne, Ph.D., Director, Business Development, Scienion US, Inc. 
  • Clay Marsh, M.D., Executive Director, Center for Personalized Health Care; Vice Dean and Senior Associate Vice President, Research, College of Medicine; Professor, Internal Medicine, Pulmonary, Allergy, Critical Care and Sleep Medicine; Director, Center for Critical Care and Respiratory Medicine, Ohio State University Medical Center 
  • Cleland C. Landolt, M.D., CMO, Singulex, Inc. 
  • Corrado Priami, Ph.D., President and CEO, The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI) 
  • Cyril H. Benes, Ph.D., Principal Investigator and Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center 
  • Dan Roden, M.D., Assistant Vice Chancellor of Personalized Medicine, Vanderbilt University  
  • Daniel Danila, M.D., Genitourinary Oncology Service, Department of Medicine,Memorial Sloan-Kettering Cancer Center   
  • Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer, Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute 
  • Daniel Hayes, M.D., Professor, Internal Medicine, University of Michigan, Ann Arbor  
  • Daniel MacArthur, Ph.D., Group Leader, Analytic and Translational Genetics Unit, Massachusetts General Hospital  
  • Daniëlle A.M. Heideman, Ph.D., Assistant Professor, Department of Pathology, Molecular Pathology Unit, VU University Medical Center  
  • Darrell Dinwiddie, Ph.D., Director, Lab Operations, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics  
  • David A. Flockhart, M.D., Ph.D.,  Harry and Edith Gladstein Chair in Cancer Genomics, Professor of Medicine, Genetics and Pharmacology; Director, Division of Clinical Pharmacology, Indiana Institute for Personalized Medicine  
  • David A. Lawrence, Ph.D., Chief, Laboratory of Immunology, Wadsworth Center, NYSDOH  
  • David A. Spiegel, Ph.D., Associate Professor of Chemistry, Yale  
  • David C. Wilbur, M.D., Professor, Pathology, Harvard Medical School and Massachusetts General Hospital  
  • David Dimmock, M.D., Assistant Professor, Pediatrics, Medical College of Wisconsin 
  • David Fung, Ph.D., Postdoctoral Research Fellow, School of Biotechnology and Biomolecular Sciences, The University of New South Wales 
  • David G. Hicks, M.D., FCAP, Professor and Director, Surgical Pathology Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center  
  • David Huntsman, M.D., FRCPC, FCCMG, Medical Director, Center for Translational & Applied Genomics, British Columbia Cancer Agency  
  • David Jackson, Vice President, Business Development, PrimeraDx 
  • David L. Dolinger, Ph.D., Executive Vice President, Business Development & Technology Realization, Seegene, Inc. 
  • David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University  
  • David A. Spiegel, Ph.D., Associate Professor of Chemistry, Yale 
  • David Steinmiller, Founder & COO, Claros Diagnostics 
  • David Tarin, M.D., Ph.D., Professor of Pathology, Director, UCSD Comprehensive Cancer Center   
  • Deepak Rajpal, Ph.D., Senior Scientific Investigator, Computational Biology, Medicines Discovery & Development, GlaxoSmithKline 
  • Dehua Pei, Ph.D., Professor of Chemistry and Biochemistry, The Ohio State University 
  • Dietrich Stephan, Ph.D., Founder & CEO, Silicon Valley Biosystems (SVBio) 
  • Dimitris Agrafiotis, Janssen R&D, Johnson & Johnson 
  • Dirk Vossen, Ph.D., Director, Applications and Q&R, Philips Digital Pathology  
  • Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center 
  • Dylan Morris, Co-Founder, Integrated Plasmonics Corporation 
  • Ed Olhava, Ph.D., Associate Director, Pre-Clinical Development, Epizyme, Inc. 
  • Edward Abrahams, President, Personalized Medicine Coalition 
  • Edward Holson, Ph.D., Director, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard 
  • Elizabeth Bruckheimer, Ph.D., Vice President Scientific Operations, Champions Oncology, Inc. 
  • Elisabeth Paietta, Ph.D., Professor of Medicine, Albert Einstein College of Medicine, Director, ECOG Leukemia Translational Research Laboratory and Leukemia Tissue Bank, Montefiore Medical Center-North Division 
  • Elizabeth A. Krupinski, Ph.D., Professor & Vice Chair of Research, Department of Medical Imaging, University of Arizona  
  • Elizabeth Farrant, Ph.D., Chief Business Officer, Cyclofluidic Ltd 
  • Elizabeth Worthey, Assistant Professor, Pediatrics & Bioinformatics Program, Human & Molecular Genetics Center, Medical College of Wisconsin  
  • Emma Lees, Ph.D., Vice President, Oncology, NIBR Site Head Emeryville, Novartis Institutes for Biomedical Research 
  • Eric A. Murphy, Ph.D., Research Investigator in Oncology Pharmacology Genomics Institute of the Novartis Research Foundation 
  • Eric F. Glassy, M.D., Medical Director, Pathology, Inc.  
  • Eric Rubin, M.D., Vice President, Clinical Research Oncology, Merck 
  • Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc. 
  • Erik Douglas, Co-Founder and CEO, CellScope 
  • Eugene Zhukovsky, Ph.D., CSO, Research, Affimed Therapeutics AG 
  • Evian Gordon, M.D., CEO, Brain Resource Company Limited  
  • Frank Diehl, Ph.D., Managing Director, Chief Scientific Officer, Inostics GmbH 
  • Frank Lovering, Ph.D., Principle Scientist II, Computational Chemistry, Pfizer 
  • Frank Pajonk, M.D., Ph.D., Associate Professor, Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles 
  • Fred Russell Kramer, Ph.D., Professor, Department of Microbiology and Molecular Genetics, Public Health Research Institute, New Jersey Medical School 
  • Fredika Robertson, Ph.D., Professor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center  
  • G. Mike Makrigiorgos, Ph.D., Director, Biophysics Laboratory and Medical Physics Division, Dana Farber Cancer Institute, Harvard Medical School  
  • Gaddy Getz, Director, Cancer Genome Computational Analysis, Broad Institute  
  • Gallen Triana-Baltzer, Ph.D., Senior Scientist, Oncology, CovX Research, Pfizer WRD  
  • Gary Clawson, M.D., Penn State University at Hershey Medical Center 
  • George I. Mias, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine
  • German Pihan, M.D., Director, Hematopathology Lab, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School 
  • Glenn A. Miller, Ph.D., Vice President and Head, Personalized Healthcare and Biomarkers, Strategy, Portfolio and Alliances, AstraZeneca Pharmaceuticals LP  
  • Gordon Springer, Ph.D., Scientific Director, Department of Computer Science, University of Missouri Bioinformatics Consortium 
  • Gorm Lisby, M.D.,  Ph.D., Senior Vice President, CSO, Science & Development, QuantiBact, Inc. (tentative) 
  • Graeme Semple, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc. 
  • Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center 
  • Gregory Zdechlik, COO, Eli Lilly & Co. 
  • Guoqing “GC” Chen, Ph.D., Vice President, Research, Biology, Igenica, Inc. 
  • Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic Medical Center 
  • Haifeng Bao, Principal Scientist, Research & Development Translational Sciences, MedImmune 
  • Hakan Sakul, Ph.D., Executive Director & Head, Diagnostics, Worldwide Research & Development, Clinical Research and Precision Medicine, Pfizer, Inc.  
  • Hakon Hakonarson, M.D., Ph.D., Director, Center for Applied Genomics, Children’s Hospital of Philadelphia  
  • Handan He, Ph.D., Dir., Pre-Clinical PK/PD, DMPK, Translational Sciences, Novartis 
  • Hannah Mamuszka, Vice President, Business Development, Exosome Diagnostics  
  • Hans-Peter Gerber, Ph.D., Executive Director, BioConjugate Discovery and Development, Oncology Research Unit East, Pfizer Worldwide R&D 
  • Harry Glorikian, Founder and Managing Partner, Scientia Advisors 
  • Harsukh Parmar, M.D., Vice President and Head, Translational and Experimental Medicine, F. Hoffmann La Roche 
  • Heidi L. Rehm, Ph.D., FACMG, Assistant Professor, Pathology, BWH and Harvard Medical School; Director, Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine  
  • Herbert Haack, Ph.D., Head, Clinical Assay Development, Cell Signaling Technology 
  • Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Oncology, University of Stanford 
  • Holger Wesche, Ph.D., Principal Scientist, Amgen, Inc. 
  • HongMei Huang, Ph.D., Director and Site Head, NIBR IT Emeryville, Novartis  
  • Hsian-Rong Tseng, Ph.D., Associate Professor, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Institute for Molecular Medicine, University of California, Los Angeles; California NanoSystems Institute  
  • Huimin Kong, Ph.D., President & CEO, BioHelix Corp. 
  • Iman Jilani, Ph.D., Associate Director, Clinical Assay Group, Global Clinical Pharmacology, Pfizer, Inc.  
  • Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis NCI, NIH 
  • Iris Schrijver, M.D., Associate Professor of Pathology and Pediatrics; Director, Molecular Pathology Laboratory, Stanford University Medical Center, Lucile Packard Children’s Hospital 
  • Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S 
  • Jacob Glanville, Ph.D., Science Director, Distributed Bio 
  • James C. Willey, M.D., Professor, Medicine and Pathology, University of Toledo College of Medicine; Consultant, Accugenomics, Inc. 
  • James Linder, M.D., Senior Associate to the President for Innovation and Economic Competitiveness; President, University Technology Development Corp.; Professor, Pathology and Microbiology, University of Nebraska 
  • Jamey Skillings, M.D., Vice President, Global Medical Affairs, Pfizer 
  • Jamie MacPherson, Ph.D., Consultant, Tessella 
  • Jamie Timmons, Ph.D., Professor, Systems Biology, Loughborough University 
  • Jan Lötvall, M.D., Ph.D., Professor, Chairman, Krefting Research Centre; President, International Society for Extracellular Vesicles (ISEV)  
  • Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation for the FDA; Former Board Chair, Lung Cancer Alliance; Cancer Survivor 
  • Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc. 
  • Jason Wakizaka, Co-Founder and Managing Member, LifeLens LLC 
  • Jay Bergeron, Program Manager, Pfizer 
  • Jaya Goyal, Ph.D., Principal Investigator, Translational Medicine, Biogen Idec 
  • Jean-Louis Viovy, Research Director, Macromolecules and Microsystems in Biology and Medicine Lab, Institute Curie   
  • Jeffrey J. Chalmers, Ph.D., Professor, Chemical & Biomolecular Engineering; Director, Analytical Cytometry Shared Resource, The Ohio State University Comprehensive Cancer Center  
  • Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech 
  • Jennie Mather, Senior Vice President, Stem Cell Technologies, Macrogenics, Inc. 
  • Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation 
  • Jeremy Packer, Ph.D., Principal Research Scientist, Scientific Informatics, Abbott Laboratories  
  • Jian Han, M.D., Ph.D., Faculty Investigator, HudsonAlpha Institute for Biotechnology, Director, R10K Project  
  • Jian Yu Rao, M.D., Professor, Pathology and Laboratory Medicine, UCLA Program on Genomics and Nutrition 
  • Jian Wang, Ph.D., President & CEO, BioFortis, Inc. 
  • Jim Hendler, Ph.D., Tetherless World Professor of Computer and Cognitive Science and Assistant Dean of Information Technology and Web Science, Rennselaer Polytechnic Institute  
  • Jing Wu, M.D., Ph.D., Assistant Professor, Department of Neurology and Neurosurgery; Co-Director, Neuro-Oncology Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina  
  • Joe W. Gray, Ph.D., Gordon Moore Professor and Chair, Biomedical Engineering, Oregon Health and Science University; Emeritus Professor, UCSF; Visiting Faculty, Lawrence Berkeley National Laboratory; Co-Director, Breast Cancer SPORE 
  • John Aletta, Ph.D., Principle Scientist, CH3 Biosystems LLC 
  • John F. Beeler, Ph.D., Director, Theranostics & Business Development, bioMerieux 
  • John Doukas, Ph.D., Senior Director, Pre-Clinical Safety and Efficacy, Vical, Inc.  
  • John Flygare, Ph.D., Senior Scientist, Discovery Chemistry, Genentech  
  • John Hunter, Ph.D., Vice President, Antibody Research & Development, Compugen, Inc. 
  • John Iafrate, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Assistant Pathologist, Massachusetts General Hospital 
  • John McDonough, CEO & President, T2 Biosystems  
  • John Swart, Ph.D., President, Exemplar Genetics 
  • John Terrett, Ph.D., CSO, Oxford Biotherapeutics, Inc.  
  • John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics 
  • Jonas Boström, Ph.D., Computational Chemist, Medicinal Chemistry, AstraZeneca 
  • Jonas Winchell, Ph.D., Laboratory Chief, Pneumonia Response and Surveillance Laboratory, Division of Bacterial Diseases, Respiratory Diseases Branch, Centers for Disease Control and Prevention (CDC) 
  • Jonathan Cheng, M.D., Director, Oncology Clinical Development, Merck 
  • Jonathan Lim, Ph.D., CEO, NexDx, Inc. 
  • Jonathan Pachter, Ph.D., Vice President & Head, Research, Verastem, Inc. 
  • Jonathan S. Mason, Ph.D., Drug Design & Computational Chemistry, Heptares Therapeutics Ltd. 
  • Jorge DiMartino, M.D., Ph.D., Executive Director, Translational Development, Celgene Corporation
  • Joseph M. Beechem, Ph.D., Senior Vice President, Research & Development, NanoString Technologies 
  • Joseph F. Donahue, Senior Vice President, Intellectual Property & Science, Thomson Reuters 
  • Joseph Szustakowski, Ph.D., Senior Group Head, Bioinformatics, Biomarker Discovery, Novartis Institutes for BioMedical Research 
  • Joshua Mandel, M.D., S.B. Research Faculty, Harvard Medical School/Children’s Hospital Informatics Program; Lead Architect for the SMART project, Harvard Medical School/Office of the National Coordinator for Health IT  
  • Joshua Stuart, Ph.D., Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz 
  • Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc. 
  • Jutta Deckert, Ph.D., Principal Scientist, Discovery Research, ImmunoGen, Inc. 
  • Kahn Rhrissorrakrai, Ph.D., Post-doctoral Researcher, Functional Genomics and Systems Biology, IBM Thomas J. Watson Research Center 
  • Karl Voelkerding, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Advanced Technology & Bioinformatics, ARUP Laboratories 
  • Kathryn Teng, M.D., FACP, Director, Center for Personalized Healthcare, Cleveland Clinic 
  • Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies 
  • Keith James, Vice President, Therapeutic Innovation, The Ferring Research Institute; Visiting Investigator, The Scripps Research Institute 
  • Keith Kaplan, M.D., Pathologist and CIO, Carolinas Pathology Group  
  • Kenneth E. Pierce, Ph.D., Senior Research Scientist, Department of Biology, Brandeis University 
  • Kenneth J. Bloom, M.D., CMO, Clarient, Inc.  
  • Kevin Bobofchak, Ph.D., Pathway Studio Product Manager, Elsevier 
  • Kevin Davies, Ph.D., Chief Editor, Bio-IT World   
  • Kim Nguyen, Ph.D., Head, Research, Quantum Cell Expansion System, Terumo BCT 
  • Kimberle C. Chapin, M.D., Lifespan Academic Medical Centers and Brown Medical School 
  • Klaus Pantel, M.D., Director, Institute of Tumor Biology, UKE 
  • Koen Van Acker, Ph.D., Scientist, Research & Assay Development, Biocartis NV 
  • Kristen M. Smith, Ph.D., Scientist II, Bionomics, Inc. 
  • Kristin Pothier, Founder, DxInsights; Partner, Health Advances  
  • Larry J. Lesko, Ph.D., FCP, Professor, Department of Pharmaceutics, University of Florida College of Pharmacy 
  • Laura J. Tafe, M.D., Assistant Director, Molecular Pathology; Assistant Professor, Department of Pathology, Dartmouth-Hitchcock Medical Center 
  • Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology, University of California San Francisco 
  • Laurence Marton, M.D., Adjunct Professor, Department of Laboratory Medicine, University of California San Francisco; Former Dean 
  • Leanna Levine, Ph.D., President and CEO, ALine, Inc. 
  • Leming Shi, Ph.D., National Center for Toxicological Research, U.S. Food and Drug Administration  
  • Len Koenig, Senior Research Associate Research Computing, Computer Science and Chemistry, ExxonMobil Research and Engineering 
  • Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc. 
  • Leslie Crews Robertson, Ph.D., Jamieson Laboratory, Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center 
  • Lewis Frey, Ph.D., Assistant Professor, Biomedical Informatics, University of Utah 
  • Lily Kong, CSO, PrimeraDx 
  • Liron Pantanowitz, M.D., Associate Professor of Pathology, University of Pittsburgh Medical Center; Department of Pathology, UPMC Shadyside  
  • Luis Diaz, M.D., Associate Professor of Oncology, Director of Translational Medicine, Ludwig Center at Johns Hopkins, Kimmel Cancer Center at Johns Hopkins  
  • Luis F. Parada, Ph.D., Diana K. and Richard C. Strauss Distinguished Chair in Developmental Biology, Southwestern Ball Distinguished Chair in Nerve Regeneration Research, University of Texas Southwestern Medical Center 
  • Lukas Karlsson, Head, Administrative Computing, Technology Leader Broad Institute  
  • Lynn R. Zieske, Ph.D., Vice President, Commercial Solutions, Singulex, Inc. 
  • Madhuri Hegde, Ph.D., FACMG, Associate Professor, Senior Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine 
  • Maham Ansari, MS, RAC, Senior Associate, Regulatory Affairs, Strategic Regulatory Services, OptumInsight, Inc. (UnitedHealth Group) 
  • Manish Muzumdar, Senior Vice President, Products, Remedy Informatics 
  • Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare 
  • Marcin Imielinski, M.D., Ph.D., Pathology, Brigham and Women’s Hospital; Meyerson Lab, Broad Institute and Dana Farber Cancer Institute 
  • Marco L. Schito, Ph.D. (contractor), Henry M. Jackson Foundation, Vaccine Clinical Research Branch, DAIDS, NIAID, NIH 
  • Marco Timmers, Ph.D., Vice President, NCEs, Biopharmaceuticals, Synthon BV 
  • Maria Vassileva, Ph.D., Scientific Program Manager, Metabolic Disorders, The Biomarkers Consortium 
  • Mark A. Collins, Ph.D., Director, Marketing, BioFortis, Inc. 
  • Mark A. DePristo, Ph.D., Associate Director, Medical and Population Genetics Analysis, Broad Institute of MIT and Harvard (on behalf of The 1000 Genomes Project Consortium) 
  • Mark A. Musen, M.D., Ph.D., Professor of Medicine, Biomedical Informatics, Stanford Center for Biomedical Informatics Research 
  • Mark L. Peterson, Ph.D., Vice President, Operations, Tranzyme Pharma 
  • Mark S. Boguski, Ph.D., Associate Professor, Center for Biomedical Informatics, Harvard Medical School 
  • Mark Zak, Ph.D., Scientist, Discovery Chemistry, Genentech 
  • Martin Baatz, Ph.D., Vice President, Marketing, Definiens 
  • Martin Leach, Ph.D., CIO, The Broad Institute 
  • Martin G. Reese, President and CEO, Omicia, Inc. 
  • Martin Seifert, Ph.D., CEO, Genomatix Software 
  • Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor 
  • Mary Bradley, Ph.D., MBA, CollaborationFinder 
  • Mats Grahn, CEO, Immunovia AB 
  • Matthew P. Jacobson, Ph.D., Professor, Pharmaceutical Chemistry, Department of Bioengineering and Therapeutic Science, University of California San Francisco 
  • Maureen Cronin, Ph.D., Industry Consultant 
  • Max S. Wicha, M.D., Distinguished Professor of Oncology and Director, University of Michigan Comprehensive Cancer Center  
  • Medical Oncology, The University of Texas MD Anderson Cancer Center 
  • Melissa R. Junttila, Ph.D., Scientist, Molecular Biology, Genentech, Inc. 
  • Mic Lajiness, Ph.D., Research Advisor, Eli Lilly  
  • Michael Barrett, Ph.D., Associate Professor, Clinical Translational Research Division; Unit Head, Oncogenomics Laboratory, TGEN 
  • Michael Detmar, M.D., Professor of Pharmacogenomics, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich 
  • Michael Fero, Ph.D., CEO, TeselaGen Bio 
  • Michael Foley, Ph.D., Director, Chemical Biology, Broad Institute  
  • Michael Roehrl, M.D., Ph.D., Associate Professor of Pathology, University of Toronto 
  • Michael Schwartz, Program Director, Business Development, Fluxion Biosystems, Inc. 
  • Michael Webb, CEO, Allegro Diagnostics, Inc. 
  • Michele Babicky, M.D., Department of Surgery, University of California San Diego  
  • Michelle R. Arkin, Ph.D., Associate Adjunct Professor, Pharmaceutical Chemistry, University of California San Francisco School of Pharmacy 
  • Mick Bhatia, Ph.D., Director and Senior Scientist, McMaster Stem Cell and Cancer Research Institute, McMaster University 
  • Mike Cummens, M.D., Chief Medical Officer, Remedy Informatics 
  • Mike Elliott, Ph.D., CEO, Atrium Research & Consulting LLC 
  • Mila McCurrach, Project Manager, NFPC, Neurofibromatosis Pre-Clinical Consortium, Children’s Tumor Foundation, Research Manager, Lustgarten Foundation 
  • Myla Lai-Goldman, Ph.D., CEO, GeneCentric Diagnostics, Inc. 
  • Nader Donzel, CTO, Biocartis  
  • Nancy Allbritton, M.D., Ph.D., Professor & Chair, UNC/NCSU Department of Biomedical Engineering; Chair, UNC CASE; Department of Chemistry, Department of Pharmacology, University of North Carolina; Department of Materials Science & Engineering, North Carolina State University  
  • Nathalie Scholler, M.D., Ph.D., Assistant Professor, Obstetrics and Gynaecology, Gyn University of Pennsylvania 
  • Nathan Price, Ph.D., Associate Professor, Institute for Systems Biology 
  • Nazneen Aziz, Ph.D., Director, Molecular Medicine, College of American Pathologists 
  • Neal Goodwin, Ph.D., Director, Research and Development, in vivo Pharmacology Services, The Jackson Laboratory 
  • Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp. 
  • Nicolo Manaresi, Ph.D., CTO, Silicon Biosystems 
  • Nils Gehlenborg, Ph.D., Research Associate, Center for Biomedical Informatics, Harvard Medical School 
  • Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital; Medical Director, Biopathology Center, Co-I and Lead Pathologist, TCGA BCR, The Research Institute at Nationwide Children’s Hospital 
  • Nitin S Patil, Scientist, Joint Unit-Molecular Oncology of Solid Tumors, DKFZ ( German Cancer Research Center) 
  • Niven Narain, Ph.D., President and CTO, Berg Pharma 
  • Noel S. Wilson, Ph.D., Senior Scientist I, Global Pharmaceutical Discovery, Hit to Lead, Abbott Laboratories 
  • Oliver Schacht, Ph.D., CEO, Curetis AG 
  • Pam Lucchesi, Ph.D., Director, Center for Cardiovascular and Pulmonary Research and Principal Investigator, Heart Center, The Research Institute at Nationwide Children’s Hospital 
  • Patrick Schnell, M.D., Safety Risk Management Lead, Pfizer  
  • Patrick Y. Mueller, Ph.D., Director, Global Coordinator, Novartis Institutes for BioMedical Research 
  • Patrizia Paterlini-Brechot, Professor, Cell Biology & Oncology, University Paris Descartes, Paris; Director, INSERM Unit 807 & CSO, Rarecells 
  • Paul Dempsey, Ph.D., Vice President, Bioengineering, Cynvenio Biosystems, Inc. 
  • Paul Denny-Gouldson, Ph.D., Vice President, Translational Medicine, IDBS 
  • Paul Holvoet, Ph.D., FAHA, FESC, Professor Biomedicine, Cardiovascular Diseases, KULeuven  
  • Paul Konstant, Manager Informatics, Janssen Pharmaceuticals 
  • Paul Polakis, Ph.D., Director & Staff Scientist, Cancer Targets, Genentech, Inc. 
  • Paul Yager, Ph.D., The Hunter and Dorothy Simmons Endowed Chair, Department of Bioengineering, University of Washington   
  • Peter Chu, Vice President, US Operations and Cancer Biology, Bionomics, Inc. 
  • Peter Houghton, Ph.D., Principal Investigator, Hematology/Oncology & Blood and Marrow Transplant (BMT) and Director, Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital 
  • Peter Kiener, Ph.D., President & CEO, Zyngenia, Inc. 
  • Peter Kuhn, Ph.D., Associate Processor, Cell Biology, The Scripps Research Institute 
  • Peter P. Lee, M.D., Professor and Associate Chair, Cancer Immunotherapeutics & Tumor Immunology (CITI), City of Hope and Beckman Research Institute, Beckman Center 
  • Peter S. Miller, COO, Genomic Healthcare Strategies 
  • Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics, Inc. 
  • Peter Yu, M.D., Medical Oncologist and Hematologist, Palo Alto Medical Foundation; Chair, Health Information Technology Work Group, The American Society of Clinical Oncology; Co-Chair, Oncology Certification Work Group, Commission for the Certification of Health Information Technology 
  • Phil Stephens, Ph.D., Vice President, Cancer Genomics, Foundation Medicine  
  • Philip D. Cotter, Ph.D., Principal, ResearchDx 
  • Philippe Corbisier, Ph.D., Scientific Project Manager, Reference Material Unit, European Commission 
  • Phyllis Post, Executive Director, Merck & Co., Inc. 
  • Pia Maria Gargiulo, Ph.D., Vice President, Pharma Partnerships, QIAGEN 
  • Pierfausto Seneci, Ph.D., Professor, Chemistry, University of Milan 
  • Premal Shah, Ph.D., Director, Business Development, Genomic Health, Inc. (tentative)  
  • Raj Singh, Ph.D., President & CEO, Vivo Biosciences, Inc. 
  • Rakesh Dixit, Ph.D., Vice President, Research & Development; Global Head, Biologics Safety Assessment, MedImmune 
  • Ramesh Ramanathan, M.D., Medical Director, The Virginia G. Piper Cancer Center Clinical Trials  
  • Ranjan Perera, Ph.D., Associate Professor and Scientific Director, Analytical Genomics and Bioinformatics, Metabolic Signaling & Disease, Sanford-Burnham Medical Research Institute 
  • Raul Brauner, Founder and CEO, Oncotree and Biotree  
  • Regina Gandour-Edwards, M.D., Director, Cancer Center Biorepository, Department of Pathology and Laboratory Medicine, UC Davis 
  • Renier J. Brentjens, M.D., Ph.D., Associate Attending Physician, Associate Member, Department of Medicine, Memorial Sloan-Kettering Cancer Center 
  • Richard A. Montagna, Ph.D., Senior Vice President, Corporate Business Development, RHEONIX, Inc. 
  • Richard Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer 
  • Richard C. Koya, M.D., Ph.D., Assistant Professor, Department of Surgery, Surgical Oncology, Member, JCCC Tumor Immunology Program Area 
  • Richard Gill, Ph.D., Director & CEO, TruTouch Technologies, Inc. 
  •  Richard E. Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer, La Jolla 
  • Richard Levenson, M.D., Professor and Vice Chair for Strategic Technologies, Department of Pathology & Laboratory Medicine, University of California Davis Medical Center 
  • Richard Ransom, Ph.D., Principal Investigator, Center for Clinical and Translational Research and Faculty, Nephrology and Urology Research Affinity Group, The Research Institute at Nationwide Children’s Hospital 
  • Richard Selden, M.D., Ph.D., CEO, NetBio 
  • Rob Mohney, Ph.D., Director, Projects (North American Pharma-Biotech), Metabolon, Inc. 
  • Robert Dunstan, Distinguished Scientist, Investigative Histology, BiogenIdec 
  • Robert J. Tressler, Ph.D., Vice President, Research & Development, Cellerant Therapeutics, Inc. 
  • Robert L. Ferris, M.D., Ph.D., FACS, Professor and Chief, Division of Head and Neck Surgery; Associate Director, Translational Research; Co-Leader, Cancer,  Immunology Program, University of Pittsburgh Cancer Institute  
  • Robin Polt, Ph.D., Professor of Chemistry & Biochemistry, BIO5, University of Arizona 
  • Roman Kischel, M.D., Principal Scientist, BiTE Technology, Amgen Research (Munich) GmbH 
  • Ronald Linnartz, Senior Director, External Collaborations, Oncology Correlative Sciences, Novartis Pharmaceuticals
  • Ross Cagan, Ph.D., Professor, Developmental & Regenerative Biology, Mount Sinai School of Medicine 
  • Rui Chen, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine 
  • Ryan Sasaki, Director, Global Strategy, ACD/Labs 
  • S. Percy Ivy, M.D., Associate Branch Chief, IDB, CTEP, National Cancer Institute 
  • Sabah Malek, Senior Regulatory Scientist, IVD/Medical Devices, Voisin Consulting Life Sciences 
  • Sandor Szalma, Head, External Innovation, R&D IT at Janssen Research & Development, LLC  
  • Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech 
  • Sanjay Joshi, CTO, Life Sciences, Isilon Storage Division, EMC Corporation 
  • Sarah Greene, Executive Director, Cancer Commons  
  • Sarah P. Thayer, M.D., Ph.D., Associate Professor, Surgery, W. Gerald Austen Scholar in Academic Surgery & Director, Pancreatic  
  • Saras Saraswathi Ph.D., Postdoctoral Research Associate, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children’s Hospital 
  • Scott Freedman, Co-Founder, Agile Diagnosis 
  • Scott C. Johnson, Ph.D., Vice President, Product Development & Manufacturing, Luminex Corporation 
  • Scott Kennedy, Ph.D., Global Head, Biomarker Development, Novartis Institutes for BioMedical Research 
  • Scott McKeown, Ph.D., R&D Consultant, Randox Pharmaceutical Services, Randox Labs Ltd  
  • Sergio E. Baranzini, Ph.D., Associate Professor, Heidrich Family and Friends Endowed Chair in Neurology, Department of Neurology, University of California San Francisco 
  • Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Pre-Clinical Research, SAIC-Frederick, Inc.  
  • Shan X. Wang, Ph.D., Professor of Materials Science & Engineering, jointly of Electrical Engineering, and by courtesy of Radiology (Stanford School of Medicine), Director, Stanford Center for Magnetic Nanotechnology  
  • Sharad K. Verma, Ph.D., Investigator, Medicinal Chemistry, GlaxoSmithKline  
  • Sharon Ungersma, Ph.D., Research Imaging Sciences, Amgen, Inc. 
  • Shashikant Kulkarni, Ph.D., Associate Professor, Department Pathology & Immunology, Washington University School of Medicine  
  • Shawn Levy, Faculty Investigator, HudsonAlpha Institute for Biotechnology  
  • Shoibal Datta, Ph.D., Associate Director, R&D Information Technology, Biogen Idec 
  • Shuqi Chen, Ph.D., CEO, IQuum, Inc. 
  • Simon Bailey, Ph.D., Sr. Director, Worldwide Medicinal Chemistry Oncology, Pfizer  
  • Simon Williams, Ph.D., Senior Scientist, Biomedical Imaging, Genentech 
  • Sitharthan Kamalakaran, Ph.D., Senior Member, Research Staff, Philips Research North America 
  • Soumitesh Chakravorty, Ph.D., Instructor, Center for Emerging Pathogens, NJMS, UMDNJ 
  • Srinivasan Parthiban, Ph.D., CEO & President, Parthys Reverse Informatics 
  • Stacy Feld, J.D., Partner, Physic Ventures 
  • Stefan Roever, CEO & Founder, Genia Technologies 
  • Stefan Scherer, M.D., Ph.D., Vice President, Clinical Development & Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG 
  • Stefanie Jeffrey, M.D., John and Marva Warnock Professor, Department of Surgery, Chief of Surgical Oncology Research, Stanford University School of Medicine   
  • Stephan Schürer, Ph.D., Center for Computational Science and Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami 
  • Stephanie Faucette, Pharm.D., Ph.D., Senior Manager, Clinical Pharmacology, Millennium Pharmaceuticals 
  • Stephen B. Squires, President, Quantum Materials Corporation 
  • Stephen Hale, Ph.D.,Vice President, Drug Discovery, Ensemble Therapeutics 
  • Stephen Little, Ph.D., Vice President, Personalized Healthcare, QIAGEN 
  • Stephen A. Williams, M.D., Ph.D., CMO, SomaLogic, Inc 
  • Steve Miller, M.D., Ph.D., Director, UCSF Clinical Microbiology Laboratory 
  • Steve Olsen, M.D., Ph.D., Global Development Team Leader, Trastuzumab Emtansine Product Development-Oncology, Genentech, Inc. 
  • Stuart Brown, Professor of Bioinformatics, New York University  
  • Sue E. Siegel, Corporate Officer and CEO, healthymagination, GE 
  • Sushmita Mukherjee, Ph.D., M.S., Assistant Professor, Biochemistry, Director, Multiphoton Microscopy Facility, Weill Medical College of Cornell University 
  • Svetlana Amirova, Ph.D., Assistant Professor, Mathematics, University of Texas at El Paso 
  • Syed A. Hashsham, Ph.D., Professor, Department of Civil and Environmental Engineering and Center for Microbial Ecology, Michigan State University 
  • Sylvia L. Asa, M.D., Ph.D., Medical Director, Laboratory Medicine Program, University Health Network and Lakeridge Health; Senior
    Symposium
     
  • Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute 
  • Terry Smith, Ph.D., Professor and Vice President for Research, Natural Sciences, National University of Ireland Galway 
  • Theo McCormick, Director, Business Intelligence, Boston Heart Diagnostics 
  • Thomas Krahn, Ph.D., Head, Global Biomarker Research, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG  
  • Thomas Van Himbergen  Ph.D.,  Content Researcher & Manager,  Elsevier 
  • Tibor van Rooij, Ph.D. Candidate, Pharmacy and Pharmaceutical Sciences, University of Alberta; former Director of Bioinformatics, Génome Québec and Montreal Heart Institute Pharmacogenomics Centre 
  • Tim Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals 
  • Todd Krueger, Strategy Leader, Medical Sciences, Life Technologies 
  • Tom Plasterer, Ph.D., Principal Informatics Scientist, Semantic Framework Lead, AstraZeneca 
  • Tom Scholl, Vice President, Research & Development, Integrated Genetics, LabCorp 
  • Tom Willis, Ph.D., CEO, Sequenta, Inc. 
  • Tony Blau, M.D., Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHCRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology   
  • Jaspal Khillan, Ph.D., Associate Professor, Microbiology and Molecular Genetics, University of Pittsburgh 
  • Topaz Kirlew, DBA, Vice President, Technical and Regulatory Affairs, Bio-Tissue 
  • Toumy Guettouche, Ph.D., Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Center for Genome Technology; Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine  
  • Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG 
  • Ulysses Balis, M.D., Ph.D., Associate Professor, Pathology, University of Michigan  
  • Una Ryan, O.B.E., Ph.D., President and CEO, Diagnostics for All (DFA) 
  • Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine, University of Leeds 
  •  Vladimir Zharov, Ph.D., D.Sc., Professor, Director, Arkansas Nanomedicine Center, University of Arkansas for Medical Sciences 
  • Walter H. Koch, Ph.D., Vice President and Head, Global Research, Roche Molecular Diagnostics   
  • Wayne Grody, M.D., Ph.D., FCAP, FACMG, Professor, Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, University of California Los Angeles School of Medicine 
  • Weiwu He, Ph.D., CEO & President, OriGene Technologies, Inc 
  • Wendy J. Levin, M.D., Director, Early Clinical Oncology, Pfizer 
  • Wen-Tien Chen, Ph.D., Research Professor, Gynecologic Oncology, Stony Brook University Medical Center  
  • William G. Loudon, M.D., Ph.D., Assistant Professor, Neurosurgery, University of California Irvine; Section Chief, Neurosurgery, Children’s Hospital of Orange County 
  • William Pignato, Global Head, Regulatory Affairs, Novartis Institutes for BioMedical Research, Inc.                 
  • William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, Personalized Medicine Institute, Moffitt Cancer Center 
  • Winston Ho, Ph.D., President, Applied BioCode, Inc. 
  • Yasuhiro Matsumura, M.D., Ph.D., Division of Developmental Therapeutics, National Cancer Center Hospital East, Tokyo, Japan 
  • Yin Lin, Ph.D., Assistant Project Scientist, Biological Sciences, University of California, San Diego 
  • Yukako Yagi, Ph.D., Director, MGH Pathology Imaging & Communication Technology (PICT) Center, Massachusetts General Hospital; Affiliated Faculty, Wellman Center for Photomedicine, Massachusetts General Hospital; Assistant Professor of Pathology, Harvard Medical SchoolYuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc. 
  • Yuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc. 

 

*as of December 13, 2012, partial list